Virtual Library

Start Your Search

Suzanne Currie



Author of

  • +

    P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.16-26 - Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f) (ID 12732)

      16:45 - 18:00  |  Author(s): Suzanne Currie

      • Abstract
      • Slides

      Background

      SABR using 60Gy/3f (or equivalent) caused high toxicity when used for cNSCLC. To determine a safe SABR dose for cNSCLC, the phase I/II RTOG 0813 trial used 50Gy/5f as a baseline. From 2013, 50Gy/5f was adopted for inoperable early-stage cNSCLC at the West of Scotland Cancer Centre, a tertiary-level oncology unit. We report our prospectively collected toxicity and efficacy data.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients with cNSCLC were identified from the radiotherapy database. cNSCLC was defined as lung cancers within 2cm of the proximal bronchial tree, or the planning target volume (PTV) abutting the mediastinal pleura/pericardium. Patient and treatment characteristics were obtained from electronic medical records. All patients received 50Gy/5f on alternate days with a volumetric arc therapy plan using TrueBeam linear accelerators. Toxicity was assessed in a centralised follow-up clinic 2 weeks, 6 weeks, 3 months, 6 months, 1 and 2 years after treatment using Common Toxicity Criteria Adverse Events version 3. Patients had a CT scan at 3 months post-treatment. Subsequent CT scans were at the discretion of the treating clinician.

      4c3880bb027f159e801041b1021e88e8 Result

      50 patients (31 females, 19 males, median age 75.1 years old) were identified with T1-2N0M0 cNSCLC. 84% were medically unfit for surgery. 40% had biopsy-proven NSCLC. All patients completed treatment on schedule. Two patients died within 90 days of treatment, one from a chest infection, the other cause of death was unknown. Table 1 describes the early and late toxicity. Over a median follow-up of 24 months, there were 20 deaths, 8 unrelated to cancer, and 12 due to cancer recurrence. The median progression free survival and overall survival are 26.0 months (95% confidence interval: 16.4, 35.6 months) and 28.6 months (95% confidence interval: 21.3, 35.8 months) respectively.

      world lung abstract table 1.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      This study has demonstrated that 50Gy/5f is a safe dose and fractionation for early-stage inoperable cNSCLC, with outcomes comparable to other series.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.16-22 - Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study (ID 13462)

      16:45 - 18:00  |  Author(s): Suzanne Currie

      • Abstract
      • Slides

      Background

      In patients with inoperable non-small cell lung cancer (NSCLC), a variety of radiotherapy regimens are used as potentially curative treatments. At the Beatson West of Scotland Cancer Centre (BWoSCC), continuous hyperfractionated accelerated radiotherapy (CHART: 54 Gy in 36 fractions over 12 days) and hypofractionated radiotherapy (55 Gy in 20 fractions over 4 weeks) are the standard fractionations. The aim of this study was to review the clinical outcomes.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective study was performed assessing clinical and dosimetric records of all radically treated NSCLC patients at the BWoSCC in 2010 and 2015. We excluded all patients who had received chemotherapy sequentially or concurrently. Patient demographics, tumour characteristics, radiotherapy and survival data were collected and analysed.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 254 patients received radical radiotherapy: 113 were treated in 2010 (52 CHART and 61 with 55/20); 141 were treated in 2015 (43 CHART and 98 with 55/20).

      Median age for CHART patients was 76 IQR (70-81), and for 55/20 patients 74 (68-79).

      Overall, CHART patients had poorer performance status (PS). 32% of CHART patients had a PS 2/3 compared to 19.5% of 55/20 patients (p<0.01). In 2010, 68% of CHART patients were PS 0/1 and 32% were PS 2/3. In 2015, 53% were PS 0/1 and 47% were PS 2 (p<0.01).

      In 2010, more CHART patients had unknown staging compared with the 55/20 patients (28% versus 4%). By 2015, there was no statistically significant difference.

      The max planning target volumes (PTV) were on average larger in 2015 than 2010. The PTV of CHART patients increased by 19.8%. The PTV of the 55/20 patients increased by 3.4%.

      Median progression free survival (progression or death) was 14.3 months 95%CI (11.0 to 18.0) for 55/20 patients and 14.6 months 95%CI (11.0 to 18.7) for CHART patients. Median overall survival was 23.2 months 95%CI (16.2 to 30.2) for 55/20 patients and 22.2 months 95%CI (14.5 to 29.2) for CHART patients.

      8eea62084ca7e541d918e823422bd82e Conclusion

      In this single centre study, we present a series of patients treated with 2 different radical radiotherapy regimens. Despite PTV volumes on average increasing from 2010 to 2015, the median survival has decreased for CHART. In our centre we introduced Stereotactic ablative radiotherapy as a new option for patients with stage I and II disease. Many patients who previously received CHART or 55/20 will now be eligible for SABR. It may be that this has changed selection criteria, with more advanced patients being put forward for CHART.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.